
NYSEARCA:XLV
This summary was created by AI, based on 3 opinions in the last 12 months.
The Health Care Select Sector SPDR Fund (XLV) has garnered positive reviews from multiple experts, showcasing its ability to outperform the S&P 500 index significantly, with a notable 12% excess return over the past three months and a year-to-date return of 26.8%. It is perceived as a safe and steady investment choice, highlighted by its low beta of 0.51, which implies lower volatility compared to the broader market. The current market trend indicates a shift away from AI sectors, giving healthcare stocks a prime opportunity for growth. Experts suggest that there is potential for short-term alpha in the healthcare sector, influenced by ongoing developments in health treatments, such as GLP-1 medications. While predictions for 2026 suggest continued growth, the current year's substantial increase makes XLV an attractive prospect for investors seeking stability amidst market fluctuations.
Just the big names in US healthcare. We have seen the bottom in here. It is one of the strongest sectors out there right now. We saw some rotation last week. It is in a secular bull market and we are at the beginning of it. It has a really good valuation. The political football that it has been is going to die down.
Which stocks for RESP and University in 8 years? He would use healthcares such as SPDR Health Care (XLV-N) or SPDR Pharma (XPH-N). These are in a secular bull market. You could also use Van Eck Vectors Biotech (BBH-Q). This gives you a little bit of mix of all 3 sectors. He would suggest 40% and 40% on the first 2 and maybe 20% in the Biotechs.
The 2nd best performing sector in the S&P 500. He likes it, but doesn't have any exposure to healthcare right now. It's a great ETF. With an $.805 Cdn dollar, he would definitely be buying the name.